424B5 filed Nov 12, 2026 at 16:30 ET
PepGen is offering 25,000,000 shares of common stock at $5.00 per share in a priced underwritten equity offering, raising gross proceeds of $125 million ($116.9 million net). The offering represents a 36.1% dilution to the 69,261,055 shares outstanding as of September 30, 2026. Proceeds will fund clinical development of PGN-EDODM1 and general corporate purposes. The offering follows positive Phase 2 FREEDOM2-DM1 results reported on November 10, 2026, and comes two days after that earnings release, signaling an urgent capital need despite the positive data.